Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 37, 2012, Pages 15030-15035

  Zoppoli, Gabriele ^a,b   Regairaz, Marie ^a   Leo, Elisabetta ^a   Reinhold, William C ^a   Varma, Sudhir ^a   Ballestrero, Alberto ^b   Doroshow, James H ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CAMPTOTHECIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DASATINIB; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; GEMCITABINE; GYRASE INHIBITOR; IMATINIB; IRINOTECAN; LAPATINIB; MELPHALAN; MITOXANTRONE; NILOTINIB; PACLITAXEL; SCHLAFEN 11 PROTEIN; SORAFENIB; SUNITINIB; TOPOTECAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE ARREST; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; DNA DAMAGE; DNA HELICASES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; MICROARRAY ANALYSIS; MICROSCOPY, CONFOCAL; NEOPLASMS; NUCLEAR PROTEINS; RNA INTERFERENCE; TOPOISOMERASE I INHIBITORS;

EID: 84866265444     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205943109     Document Type: Article

References (23)

1. Kantarjian H, et al.; International STI571 CML Study Group (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652.
2. Dematteo RP, et al.; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, doubleblind, placebo-controlled trial. Lancet 373:1097-1104.
3. Piccart-Gebhart MJ, et al.; Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672.
4. Romond EH, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684.
5. Coiffier B, et al. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045.
6. Urruticoechea A, Smith IE, DowsettM (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220.
7. Bonner WM, et al. (2008) GammaH2AX and cancer. Nat Rev Cancer 8:957-967.
8. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
9. Shankavaram UT, et al. (2009) CellMiner: A relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10:277.
10. Holbeck SL, Collins JM, Doroshow JH (2010) Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 9:1451-1460.
11. Liu H, et al. (2010) mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 9:1080-1091.
12. Reinhold WC, et al. (2010) Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 70:2191-2203.
13. Reinhold WC, et al. (2012) CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcripts and drug patterns in the NCI-60 cell line set. Cancer Res 72:3499-3511.
14. Bussey KJ, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5:853-867.
15. Antony S, et al. (2007) Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 67:10397-10405.
16. Bustos O, et al. (2009) Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene 447(1):1-11.
17. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y (1994) Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 211:314-321.
18. Yoshihara K, et al. (2010) Gene expression profi le for predicting survival in ad-vanced- stage serous ovarian cancer across two independent datasets. PLoS ONE 5:e9615.
19. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607.
20. Wagner L (2011) Camptothecin-based regimens for treatment of ewing sarcoma: Past studies and future directions. Sarcoma 2011:957957.
21. Grimer R, Judson I, Peake D, Seddon B (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182.
22. Garnett MJ, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575.
23. Weinstein JN (2012) Drug discovery: Cell lines battle cancer. Nature 483:544-545.